CTMC Partners with ScaleReady for Combatting Manufacturing Barriers

ScaleReady and CTMC have announced a partnership as of Oct. 4, 2023 to help lessen the manufacturing barriers that are restricting life-saving cell and gene therapies from reaching more patients by integrating cutting-edge automation tools. According to the press release, the agreement will enable CTMC to strategically scale the recently completed good manufacturing practice facility to drive high-throughput manufacturing utilizing the automated, closed system capabilities of the Fresenius Kabi Lovo and Cue cell processing systems.

ScaleReady is defined as delivering rapid expansion of immune cells at any scale by reducing complexity and cost while providing superior repeatability and cell quality. Founded in 2020, ScaleReady is a joint venture of Bio-Techne, Fresenius Kabi, and Wilson Wolf, according to the press release.

“CTMC sees tremendous value in using products with a solid track record of clinical and commercially approved cell therapy successes. ScaleReady’s expertise and platform access will help us to leverage innovative technologies, like the Lovo, for our cell therapy process,” said Laine Linden, head of CTMC Technical Operations, in a press release. “With the addition of the Fresenius Kabi Cue to our manufacturing platform, we hope to drive down variability and increase the number of patients we can successfully treat by automating and closing the final fill and finish steps of our cell therapy products.”

“We are honored to partner with CTMC and support their work to commercialize therapies from some of the world's leading cancer experts. By providing this state-of-the-art facility and their technical experts with the Cue system, we can functionally close the critical final fill and finish steps, which have historically been manual and open processes,” said Josh Ludwig, global commercial director, ScaleReady, in a press release. “This leading-edge technology brings a new level of automation and scalability. Our expanded partnership with CTMC will significantly impact not only the research and the organization but also the patients in need of life-saving therapies.”

Source: ScaleReady